CD274 and neoplasm: For these reasons, diprovocim, a TLR1/2 agonist with superior adjuvanticity, is synergized with OVA and anti-PD-L1 therapy to inhibit the growth of melanoma tumors, generating long-term anti-tumor memory and prolonged survival [159].